CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Evaluate recently presented clinical research findings to determine their effect on the current care of patients with localized or metastatic breast cancer.
  • Assess the results of genomic assays and other relevant patient- and treatment-related factors to personalize adjuvant systemic therapy for individuals with newly diagnosed ER-positive breast cancer.
  • Review published research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies and of PARP inhibitors for patients with localized triple-negative breast cancer (TNBC), and employ this information to make appropriate treatment recommendations.
  • Implement a long-term clinical plan for the care of patients with metastatic HER2-positive breast cancer, incorporating existing and recently approved anti-HER2 therapies.
  • Evaluate relevant biological, patient and treatment-related factors to personalize the selection and sequencing of therapy for individuals diagnosed with ER-positive, HER2-negative metastatic breast cancer.
  • Evaluate published research findings guiding the selection and sequencing of available therapeutic agents for patients with metastatic TNBC.
  • Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for localized and metastatic breast cancer.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Aditya Bardia, MD, MPH
  Director, Breast Cancer Research Program
  Associate Professor
  Harvard Medical School
  Attending Physician
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi.
  
  Sara M Tolaney, MD, MPH
  Chief, Division of Breast Oncology
  Associate Director, Susan F Smith Center for Women's Cancers
  Senior Physician
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Aadi Bioscience, ARC Therapeutics, Artios Pharma Limited, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Jazz Pharmaceuticals Inc, Lilly, Menarini Group, Merck, Myovant Sciences, Natera Inc, Novartis, OncXerna Therapeutics Inc, Pfizer Inc, Reveal Genomics, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Umoja Biopharma, Zentalis Pharmaceuticals, Zetagen, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer Inc, Seagen Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, and Merck.
  
  Release date: November 2023
  Expiration date: November 2024